Condition: Women's Health: Neoplasm of Breast · Sponsor: Umbria Bioengineering Technologies
This is an open, multicentric, interventional, prospective, non-randomized clinical investigation. The first aim of the study is to confirm that MammoWave reaches sensitivity\>75% and specificity\>90% in breast cancer (BC) detection on 10.000 volunteers undergoing regular screening programs.
This description comes directly from the study's public registry record.
Gianluigi Tiberi · 0039 3490564302 · gianluigi@ubt-tech.com
Sabatino Tiberi · s.tiberi@ubt-tech.com
Always discuss trial participation with your own doctor first.
| IRCCS Policlinico San Martino | Genova, Genova, Italy | Recruiting |
| Ospedale San Giovanni Battista - USL Umbria 2 | Foligno, Perugia, Italy | Recruiting |
| Az. San. Univ. Giuliano Isontina (ASU GI) | Trieste, Italy | Recruiting |
| Pomeranian Medical University Hospital | Szczecin, Poland | Recruiting |
| Champalimaud Foundation | Lisbon, Portugal | Recruiting |
| Clínica Dr. Passos Ângelo in Lisbon | Lisbon, Portugal | Recruiting |
| Hospital Universitario Reina Sofía- Córdoba | Córdoba, Spain | Recruiting |
| Hospital General Universitario Morales Meseguer | Murcia, Spain | Recruiting |
| Complejo Hospitalario Universitario de Toledo | Toledo, Spain | Recruiting |
| Diagnostic and Interventional Radiology, University Hospital Zurich | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06291896